结直肠癌解剖位置与抗EGFR抗体疗效的汇总分析
该研究基于ARCAD数据库12项随机对照试验的个体患者数据,纳入2867例RAS野生型转移性结直肠癌患者,比较一线双药化疗联合抗EGFR治疗或贝伐珠单抗的疗效。结果显示抗EGFR治疗在右侧结肠癌未改善OS或PFS,在RAS/BRAF野生型右侧结肠癌中PFS更差,而在左侧结直肠癌中显著改善OS和ORR,直肠获益最明显。
要点
- RAS野生型右侧结肠癌中抗EGFR治疗未改善OS或PFS。
- RAS/BRAF野生型右侧结肠癌中抗EGFR治疗PFS更差。
- RAS野生型左侧结直肠癌中抗EGFR治疗显著改善OS和ORR。
核心结论
- 抗EGFR治疗在转移性结直肠癌中的疗效存在超出传统左右半分类的区域内异质性。
- 解剖肿瘤位置可能反映左右半二分法未完全捕捉的生物学差异。
研究设计与样本
- 基于ARCAD数据库12项随机对照试验的个体患者水平数据汇总分析。
- 纳入接受一线双药化疗联合抗EGFR治疗或贝伐珠单抗的RAS野生型转移性结直肠癌患者。
- 共纳入2867例患者,其中右侧结肠癌815例,左侧结直肠癌2052例。
主要发现
- 在RAS野生型右侧结肠癌中,抗EGFR治疗与贝伐珠单抗相比未改善OS或PFS。
- 在RAS/BRAF野生型右侧结肠癌中,抗EGFR治疗与更差的PFS相关。
- 在RAS野生型左侧结直肠癌中,抗EGFR治疗显著改善OS和ORR,PFS无显著差异。
- 片段水平分析(N=1491)显示右侧结肠癌内无显著异质性,但中位OS在各亚部位间数值上有差异。
- 在左侧结直肠癌中,OS获益在直肠最为明显。
临床怎么用
- RAS野生型右侧结肠癌一线治疗选择抗EGFR抗体需谨慎,可能不优于贝伐珠单抗。
- RAS野生型左侧结直肠癌尤其是直肠癌可从抗EGFR治疗中获得OS和ORR获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The selection of biologic therapies in metastatic colorectal cancer (mCRC) is traditionally guided by right-left classification; however, this binary classification may not fully capture heterogeneity in responsiveness to anti-epidermal growth factor receptor (EGFR) therapy. We evaluated whether treatment efficacy varies across detailed anatomical tumour segments. METHODS: Individual patient-level data from 12 randomised controlled trials in the ARCAD database were analysed. Patients with RAS wild-type (RAS-WT) mCRC receiving first-line doublet chemotherapy plus anti-EGFR therapy or bevacizumab were included. The primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS) and objective response rate (ORR). RESULTS: A total of 2867 patients were included (815 right-sided colon cancer [RSC]; 2052 left-sided colorectal cancer [LSC]). In RAS-WT RSCs, anti-EGFR therapy was not associated with improved OS or PFS versus bevacizumab. In RAS/BRAF-WT RSCs, anti-EGFR therapy was associated with inferior PFS. In contrast, in RAS-WT LSCs, anti-EGFR therapy significantly improved OS and ORR, without a significant difference in PFS. Segment-level analyses (N = 1491) showed no significant heterogeneity within RSCs, although median OS numerically varied across subsites. Within LSCs, the OS benefit was most pronounced in the rectum. CONCLUSIONS: The efficacy of anti-EGFR therapy in mCRC appears to exhibit additional intraregional heterogeneity beyond the conventional right-left classification. These findings suggest that anatomical tumour location may reflect underlying biological differences not fully captured by this binary classification.
引用
- Iguchi K, Yamazaki K, Misumi T, et al. Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials. Eur J Cancer. 2026. PMID: 42372637. doi:10.1016/j.ejca.2026.116886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。